Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non‐small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non‐small cell lung cancer

Published:2023-10 Issue: Volume:196 Page:106921
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Guo Wei,Zhou Bolun,Zhao Liang,Huai Qilin,Tan Fengwei,Xue Qi,Lv Fang,Gao Shugeng,He Jie

Funder

Chinese Academy of Medical Sciences Initiative for Innovative Medicine

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference39 articles.

1. Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: a population-based study;Zhou;EBioMedicine,2022

2. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer;Chaft;J. Clin. Oncol.,2022

3. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials;Song;J. Thorac. Oncol.,2010

4. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer;Burdett;Cochrane Database Syst. Rev.,2015

5. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches;Cortiula;Ann. Oncol.,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma;Frontiers in Immunology;2024-08-05

2. Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer;Journal for ImmunoTherapy of Cancer;2024-08

3. Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma;Biomedicines;2024-03-17

4. Genomic characteristics and immune landscape of super multiple primary lung cancer;eBioMedicine;2024-03

5. Non-coding RNAs in cancer immunotherapy: A solution to overcome immune resistance?;Progress in Molecular Biology and Translational Science;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3